Neurocrine Biosciences | NBIX - Des Atouts





Des Atouts Changement Date
AbbVie USD 135.12B 1.35B 2026-06
Acadia Pharmaceuticals USD 1.74B 137.67M 2026-06
Agios Pharmaceuticals USD 1.11B 76.57M 2026-06
ALKERMES USD 4.39B 135.05M 2026-06
Alnylam Pharmaceuticals USD 5.56B 429.22M 2026-06
Amgen USD 95.64B 3.14B 2026-06
Biogen USD 32.09B 2.6B 2026-06
BioMarin Pharmaceutical USD 11.72B 3.13B 2026-06
Cytokinetics USD 1.92B 651.07M 2026-06
Enanta Pharmaceuticals USD 329.5M 48.77M 2025-12
Exelixis USD 2.49B 99.36M 2026-06
Gilead Sciences USD 49.36B 6.92B 2026-06
Halozyme Therapeutics USD 2.58B 95.31M 2026-06
Incyte USD 7.87B 533.53M 2026-06
Ionis Pharmaceuticals USD 2.99B 455.5M 2026-06
Nektar Therapeutics USD 763.27M 482.86M 2026-03
Neurocrine Biosciences USD 5.36B 452.9M 2026-06
Pfizer USD 201.13B 6.49B 2026-06
Prothena USD 302.58M 47.32M 2026-06
Regeneron Pharmaceuticals USD 41.73B 861.8M 2026-06
Repligen USD 2.95B 19.41M 2026-06
Rigel Pharmaceuticals USD 242.53M 35.8M 2025-09
Sarepta Therapeutics USD 3.19B 9.58M 2026-06
Teva Pharmaceutical Industries USD 39.86B 183M 2026-06
Ultragenyx Pharmaceutical USD 1.26B 32M 2026-06
Vertex Pharmaceuticals USD 27.42B 938.9M 2026-06